Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > BioNanomatrix Adds Genomic Science and Business Expertise

Abstract:
Bring World-Class Expertise in Structural Genomic Variation and Successful Commercialization of Innovative Research Technologies

BioNanomatrix Adds Genomic Science and Business Expertise

Philadelphia, PA | Posted on September 16th, 2009

BioNanomatrix, Inc., a developer of breakthrough nanoscale technologies for biomedical research, molecular diagnostics and personalized medicine, today announced that Dr. Charles Lee and Dr. David L. Barker have joined the company's advisory team. Dr. Lee is a pioneer in the field of structural genomic variation working at Brigham and Women's Hospital, Harvard Medical School and the Broad Institute. Dr. Barker, the former chief scientific officer at Illumina, Inc., has had a distinguished career spearheading the development and commercialization of innovative tools for life sciences research.

"The additions of Charles Lee and David Barker to our advisory team mark an important step in BioNanomatrix's transition from a development stage to a commercial company," said Michael Boyce-Jacino, Ph.D., chief executive officer of BioNanomatrix. "Our platform has the potential to revolutionize the analysis of structural genomic variation, and there is no one more knowledgeable to help guide our efforts in this field than Dr. Lee. Similarly, Dr. Barker's three decades of experience in successfully commercializing highly innovative life sciences technologies will be very valuable as we prepare for market introduction of our single-molecule whole genome imaging and analysis platform. We welcome these outstanding individuals to our advisory team and look forward to working with them to advance our product development programs."

Dr. Lee is currently the director of cytogenetics for the Harvard Cancer Center , an associate professor of pathology at Harvard Medical School and an associate member of the Broad Institute at the Massachusetts Institute of Technology. He holds a cross-appointment as an adjunct associate professor at the Chinese University of Hong Kong . Dr. Lee received his Ph.D. from the University of Alberta and was a postdoctoral fellow at Cambridge University and at Harvard Medical School . He has authored over 100 publications in leading scientific journals and is an associate editor for the American Journal of Human Genetics. Dr. Lee serves on numerous committees—he is the chair of the American Society of Human Genetics Program Committee, founding principal investigator of the Genomic Structural Variation Consortium and co-chair of the Structural Genomic Variation Analysis group for the 1000 Genomes Project, an ambitious consortium that is sequencing the genomes of as many as two thousand people from around the world to create the most detailed and medically useful picture to date of human genomic variation (www.1000genomes.org).

"The more we learn about the human genome, the greater our appreciation of the key role that structural variation plays in disease and health," said Dr. Lee. "The whole genome imaging and analysis platform being developed by BioNanomatrix is uniquely well-suited to identifying important structural variations in the genome and to producing high resolution maps of these variations. This technology has the potential to help accelerate genomic research, and I look forward to working with BioNanomatrix to ensure that it is optimally useful to researchers."

Dr. Lee's laboratory was one of two groups to discover the widespread presence of structural variation (in the form of copy number variants, or CNVs) in the genome, and the Genomic Structural Variation Consortium that he helped to establish subsequently published a first generation CNV map for the human genome. Dr. Lee has received many awards, including the Inaugural Team Award from the American Association for Cancer Research in 2007 for "the landmark discovery of recurrent gene fusions in prostate cancer." In the following year, he became the youngest-ever recipient of the Ho-Am Prize in Medicine, characterized as the "Korean Nobel Prize," for his pioneering work in human genomic variation.

Dr. David Barker formerly was vice president and chief scientific officer at Illumina, Inc., where he played a major role in the development and successful commercial launch of a succession of innovative research technologies. Since its founding in 1998, Illumina has been a leader in the commercialization of novel technologies for the analysis of genomic variation and function. Dr. Barker currently is a member of Illumina's Scientific Advisory Board and also serves on the board of directors of a number of life sciences companies. Prior to Illumina, Dr. Barker was vice president and chief science advisor at Amersham Biosciences, now part of General Electric. Previously, Dr. Barker held senior positions, including vice president of research and business development, at Molecular Dynamics, Inc.

"BioNanomatrix is developing a novel nanoscale approach that leverages its proprietary semiconductor technology to enable important genomic analyses that are currently not feasible," said Dr. Barker. "The technology could be very valuable as a research tool and ultimately, for routine use in clinical medicine applications. I welcome the opportunity to work with the BioNanomatrix team as they move towards commercializing this potentially game-changing technology."

Earlier in his career, Dr. Barker was an assistant professor at the University of Oregon and an associate professor at Oregon State University. Dr. Barker holds a B.S. with honors from the California Institute of Technology and a Ph.D. from Brandeis University. He was a postdoctoral fellow at Harvard Medical School.

####

About BioNanomatrix
BioNanomatrix is developing breakthrough nanoscale whole genome imaging and analytic platforms for applications in biomedical research, genetic diagnostics and personalized medicine. The company is applying its expertise in nanochips, nanodevices and nanosystems to develop its patented platform technology to provide fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Its current development efforts include a NIST-ATP funded project to sequence the human genome at a cost of $100. The company also receives funding from the National Institutes of Health. BioNanomatrix’s technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pennsylvania.

For more information, please click here

Contacts:
Barbara Lindheim
GendeLLindheim BioCom Partners LLC
48 Wall Street, suite 1100
New York, NY 10005
212.918.4650 (office)
917.355.9234 (mobile)
www.biocompartners.com

Copyright © BioNanomatrix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Tissue regeneration using anti-inflammatory nanomolecules August 22nd, 2014

A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy August 22nd, 2014

Ultra-short pulse lasers & Positioning August 21st, 2014

Malvern’s Dr Alan Rawle talks TLAs in plenary lecture at Particulate Systems Analysis conference August 21st, 2014

Nanomedicine

Tissue regeneration using anti-inflammatory nanomolecules August 22nd, 2014

Ultra-short pulse lasers & Positioning August 21st, 2014

Nanotechnology Helps Production of Super Adsorbent Polymers August 21st, 2014

Newly-Developed Nanobiosensor Quickly Diagnoses Cancer August 20th, 2014

Announcements

Tissue regeneration using anti-inflammatory nanomolecules August 22nd, 2014

A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy August 22nd, 2014

Malvern’s Dr Alan Rawle talks TLAs in plenary lecture at Particulate Systems Analysis conference August 21st, 2014

Water window imaging opportunity: A new theoretical study elucidates mechanisms that could help in producing coherent radiations, ultimately promoting high-contrast imaging of biological samples August 21st, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Nanometrics CFO to Resign for New Job Opportunity August 8th, 2014

California Nanotechnologies Appoints Dr. Enrique Lavernia to the Board August 6th, 2014

ACS Biomaterials Science & Engineering™: Brand-new journal names editor July 29th, 2014

Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014

Nanobiotechnology

The channel that relaxes DNA: Relaxing DNA strands by using nano-channels: Instructions for use August 20th, 2014

Сalculations with Nanoscale Smart Particles August 19th, 2014

Interaction between Drug, DNA for Designing Anticancer Drugs Studied in Iran August 17th, 2014

Scientists fold RNA origami from a single strand: RNA origami is a new method for organizing molecules on the nanoscale. Using just a single strand of RNA, this technique can produce many complicated shapes. August 14th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE